Tanabe Pharma Corporation: Renal Insufficiency, Chronic trials

The registry lists 13 Renal Insufficiency, Chronic studies with Tanabe Pharma Corporation as lead sponsor. 0 are open to participants now and 9 have results posted.

Phase 1 1Phase 3 12(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Drug-Drug Interaction Study to Evaluate the Effect of Colestilan on the Pharmacokinetics of Single Doses of Candesartan Cilexetil in Healthy SubjectsCompletedNCT01976572Phase 1Results posted
• Efficacy and Safety Study of MCI-196 Versus Simvastatin for Dyslipidaemia in Chronic Kidney Disease (CKD) Subjects on DialysisCompletedNCT00858637Phase 3Results posted
• Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With HyperphosphatemiaCompletedNCT00772382Phase 3Results posted
• A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With HyperphosphatemiaCompletedNCT00542815Phase 3Results posted
• A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and DyslipidaemiaCompletedNCT00542386Phase 3Results posted
• A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With HyperphosphatemiaCompletedNCT00506441Phase 3Results posted
• A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease Including Assessment of Quality of Life (EPPIC-2)CompletedNCT00501046Phase 3Results posted
• A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1)CompletedNCT00500682Phase 3Results posted
• A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With HyperphosphatemiaCompletedNCT00416520Phase 3Results posted
• Safety and Tolerability Study of MCI-196TerminatedNCT01818687Phase 3
• Long-term Extension Study of MCI-196TerminatedNCT01814917Phase 3
• Dose-finding Study of MCI-196TerminatedNCT01814904Phase 3
• A Phase III, Multi-Centre, Randomised, Placebo-Controlled Study in Combination With Ca-based P Binders in Patients With HyperphosphatemiaTerminatedNCT00451295Phase 3